D.E. Shaw & Co
CBAY

D.E. Shaw & Co’s Cymabay Therapeutics CBAY Stock Holding History

D.E. Shaw & Co’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-636,897
Closed -$15M – 4860
2023
Q4 		$15M Sell
636,897
-161,112
-20% -$2.87M 0.01% 1103
2023
Q3 		$11.9M Buy
798,009
+105,608
+15% +$1.4M 0.01% 1164
2023
Q2 		$7.58M Buy
692,401
+143,357
+26% +$1.33M 0.01% 1566
2023
Q1 		$4.79M Buy
549,044
+280,849
+105% +$2.25M 0.01% 1965
2022
Q4 		$1.68M Buy
268,195
+43,582
+19% +$166K ﹤0.01% 3075
2022
Q3 		$786K Sell
224,613
-40,728
-15% -$146K ﹤0.01% 3759
2022
Q2 		$782K Sell
265,341
-44,941
-14% -$107K ﹤0.01% 3792
2022
Q1 		$965K Buy
310,282
+63,494
+26% +$200K ﹤0.01% 3948
2021
Q4 		$835K Sell
246,788
-101,910
-29% -$387K ﹤0.01% 4081
2021
Q3 		$1.27M Sell
348,698
-248,029
-42% -$977K ﹤0.01% 3409
2021
Q2 		$2.6M Sell
596,727
-359,794
-38% -$1.6M ﹤0.01% 2669
2021
Q1 		$4.34M Sell
956,521
-304,228
-24% -$1.64M ﹤0.01% 1958
2020
Q4 		$7.24M Sell
1,260,749
-423,737
-25% -$3.21M 0.01% 1584
2020
Q3 		$12.2M Sell
1,684,486
-1,700,686
-50% -$9.09M 0.01% 1111
2020
Q2 		$11.8M Buy
3,385,172
+965,288
+40% +$2.79M 0.01% 1091
2020
Q1 		$3.58M Buy
2,419,884
+398,332
+20% +$669K 0.01% 1722
2019
Q4 		$3.96M Buy
2,021,552
+1,329,633
+192% +$4.99M ﹤0.01% 1913
2019
Q3 		$3.54M Buy
691,919
+457,244
+195% +$2.77M ﹤0.01% 1906
2019
Q2 		$1.68M Buy
234,675
+222,471
+1,823% +$2.52M ﹤0.01% 2353
2019
Q1 		$162K Buy
12,204
+1,738
+17% +$18.5K ﹤0.01% 3428
2018
Q4 		$82K Buy
+10,466
New +$99.6K ﹤0.01% 3655

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's CBAY Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 636,897 shares — an estimated $15M sold.

D.E. Shaw & Co first reported a position in CBAY in Q4 2018 and held it in 21 quarters. The position peaked at $15M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 636,897 Cymabay Therapeutics shares in Q1 2024, an estimated $15M.
  • D.E. Shaw & Co first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 21 quarters.
  • D.E. Shaw & Co's Cymabay Therapeutics position peaked at $15M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.